{"id":1599,"date":"2025-07-23T16:42:37","date_gmt":"2025-07-23T16:42:37","guid":{"rendered":"https:\/\/retrotradingreport.com\/index.php\/2025\/07\/23\/heres-why-iova-stock-surged-32-today-and-why-the-rally-might-not-be-over\/"},"modified":"2025-07-23T16:42:37","modified_gmt":"2025-07-23T16:42:37","slug":"heres-why-iova-stock-surged-32-today-and-why-the-rally-might-not-be-over","status":"publish","type":"post","link":"https:\/\/retrotradingreport.com\/index.php\/2025\/07\/23\/heres-why-iova-stock-surged-32-today-and-why-the-rally-might-not-be-over\/","title":{"rendered":"Here\u2019s why Iova stock surged 32% today and why the rally might not be over"},"content":{"rendered":"
<\/div>\n

Iova stock rallied 32% on Wednesday, snapping out of a long, sluggish stretch that had frustrated investors for months.<\/p>\n

The Iovance Biotherapeutics (NASDAQ: IOVA) shares have been stuck in a tight range after a rough year, but today\u2019s move was sharp enough to turn heads.<\/p>\n

There wasn\u2019t a single headline driving the surge, but traders pointed to growing buzz around the company\u2019s pipeline and speculation that regulatory progress could be closer than expected.<\/p>\n

Some also saw it as a technical breakout, triggering a wave of buying, including short covering.<\/p>\n

Iova stock: What’s behind the rally?<\/h2>\n

Iovance Biotherapeutics is suddenly one of the most talked-about names on the NASDAQ and for good reason.<\/p>\n

A mix of heavy short interest and a genuinely improving outlook is putting serious momentum behind the stock.<\/p>\n

With roughly 34.5% of its float sold short, IOVA has all the makings of a classic short squeeze play.<\/p>\n

But this isn\u2019t just a technical move. The fundamentals are shifting too fast.<\/p>\n

The biggest tailwind? The FDA recently rejected Replimune\u2019s RP1, a competing skin cancer treatment.<\/p>\n

That clears the runway for Iovance\u2019s newly approved Amtagvi, giving it a real shot at becoming the go-to therapy for advanced melanoma.<\/p>\n

With a key rival out of the picture (at least for now), Iovance has room to gain market share more quickly than expected.<\/p>\n

The company\u2019s tone is also turning more upbeat. Executives say they\u2019re on track to beat Q2 guidance, citing steady physician demand and more patient starts since April.<\/p>\n

Looking further ahead, Iovance is aiming high: management is targeting $1 billion in annual revenue and gross margins north of 80% as the treatment gains traction with earlier-stage patients and in community clinics, not just top-tier cancer centers.<\/p>\n

It\u2019s still early days, and biotech is never without risk.<\/p>\n

But for now, IOVA looks like more than just another short squeeze. The fundamentals are catching up with the hype.<\/p>\n

What analysts say?<\/h2>\n

Wall Street is leaning positive<\/a> on Iova stock, though with a notable spread in expectations that underscores the stock\u2019s high-risk, high-reward profile.<\/p>\n

Of the 16 analysts currently covering the stock, a solid 82% rate it a \u201cStrong Buy\u201d or \u201cBuy,\u201d with no \u201cSell\u201d ratings in sight.<\/p>\n

About 19% have it pegged as a \u201cHold,\u201d suggesting general optimism tempered by some lingering caution.<\/p>\n

Price targets, however, are all over the map.<\/p>\n

Chardan Capital\u2019s Geulah Livshits is among the most bullish, calling for a $25 price, more than double where the stock trades now.<\/p>\n

Others have landed in a more modest $8 to $20 range.<\/p>\n

Then there\u2019s UBS, which is holding the low end of the spectrum with a $2 target, reflecting skepticism around the durability of Iovance\u2019s early momentum and long-term commercial viability.<\/p>\n

Some analysts are highlighting IOVA\u2019s relatively low price-to-sales ratio, framing it as a potential value play if the company can keep building revenue and commercial traction.<\/p>\n

A lot will hinge on the upcoming Q2 earnings report, where strong results could either validate the bullish case or reinforce the concerns of skeptics.<\/p>\n

The post Here’s why Iova stock surged 32% today and why the rally might not be over<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Iova stock rallied 32% on Wednesday, snapping out of a long, sluggish stretch that had frustrated investors for months.The Iovance Biotherapeutics (NASDAQ: IOVA) shares have been stuck in a tight range after a rough year, but today\u2019s move was sharp enough to turn heads.There wasn\u2019t a single headline driving the surge, but traders pointed to…<\/p>\n","protected":false},"author":1,"featured_media":1600,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-1599","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing"],"_links":{"self":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/posts\/1599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/comments?post=1599"}],"version-history":[{"count":0,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/posts\/1599\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/media\/1600"}],"wp:attachment":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/media?parent=1599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/categories?post=1599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/tags?post=1599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}